Combination composition, comprising as active ingredients L-carnitine or propionyl L-carnitine, for the prevention or treatment of chronic venous insufficiency

1. A method for treating diseases of the veins, wherein the diseases of the veins are selected from the group consisting of chronic venous insufficiency and chronic venous disease, the method comprising: administering to a patient in need thereof an effective amount of a combination composition comprising L-carnitine or propionyl L-carnitine or a salt thereof, troxerutine, diosmine and hesperidine.

2. The method of claim 1 , wherein the composition further comprises one or more pharmaceutically acceptable excipient.

3. The method of claim 1 , wherein the composition comprises:

from 10 to 3000 mg of L-carnitine or propionyl L-carnitine,

from 50 to 900 mg of troxerutine,

from 50 to 900 mg of diosmine, and

from 10 to 500 mg of hesperidine.

4. The method of claim 3 , wherein the L-carnitine or the propionyl L-carnitine is in a dose of from 50 mg to 400 mg.

5. The method of claim 3 , wherein the L-carnitine or propionyl L-carnitine is in a dose of 136 mg.

6. The method of claim 3 , wherein the troxerutine is in a dose of from 200 mg to 400 mg.

7. The method of claim 3 , wherein the troxerutine is in a dose of 300 mg.

8. The method of claim 3 , wherein the diosmine is in a dose of from 200 mg to 400 mg.

9. The method of claim 3 , wherein the diosmine is in a dose of 300 mg.

10. The method of claim 3 , wherein the hesperidine is in a dose of from 50 mg to 200 mg.

11. The method of claim 3 , wherein the hesperidine is in a dose of 100 mg.

12. The method of claim 1 , wherein the composition further comprises co-enzymes, mineral substances, antioxidants, vitamins and anticlotting agents.

13. The method of claim 1 , wherein the treatment is for complications of chronic venous insufficiency or chronic venous disease, wherein said complications are selected from the group consisting of: swelling and inflammation of veins in the rectum, anus and vulva; venous hypertension; increased permeability; oedema; capillary damage; skin changes; venous leg ulcers; swelling ankles; heavy legs; varicose veins; swelling leg; ulcers; vein thrombosis; phlebitis; thrombo-phlebitis; pulmonary embolus and hemorrhoids.

14. The method of claim 1 , wherein the salt of L-carnitine or propionyl L-carnitine is selected from the group consisting of: chloride, bromide, orotate, aspartate, acid aspartate, acid citrate, magnesium citrate, phosphate, acid phosphate, fumarate and acid fumarate, magnesium fumarate, lactate, maleate and acid maleate, oxalate, acid oxalate, pamoate, acid pamoate, sulphate, acid sulphate, glucose phosphate, tartrate and acid tartrate, glycerophosphate, mucate, magnesium tartrate, 2-amino-ethanesulphonate, magnesium 2-amino-ethane-sulphonate, methanesulphonate, choline tartrate, trichloroacetate and trifluoroacetate.

15. The method of claim 1 , wherein the combination composition is for oral, parenteral, intravenous, topical and/or transdermal administration.

16. The method of claim 15 , wherein the combination composition is for oral administration.